^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
Published date:
11/29/2022
Excerpt:
Data from CRC patients for whom RAS mutational status was analyzed...Treatment with bevacizumab (BV) increased significatively mPFS (p=0.036) and mOS (p=0.019) of the entire population with a substantial benefit in mOS for G12V mutation (p=0.031)….BV was added in 60.4% (n=84) of 139 patients with an exon 2 mutation and showed a concrete increase in survival with a mOS of 27.2 months (IC 95% 20.7-39.4) versus 18.0 months...
DOI:
https://doi.org/10.3389/fonc.2022.1055019
